How much is a share of CRDL worth?
Apr 11, 2022 · Cardiol Therapeutics saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 319,600 shares, a drop of 20.5% from the March 15th total of 401,900 shares. Based on an average daily trading volume, of 315,300 shares, the days-to-cover ratio is presently 1.0 days.
Should you buy Cardiol Therapeutics Inc (CRDL-T) stock?
Apr 04, 2022 · Why is Cardiol Therapeutics INc. stock dropping? Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
What does CRDL-t stand for?
Mar 29, 2022 · 3 analysts have issued 12 month price targets for Cardiol Therapeutics' shares. Their forecasts range from C$4.00 to C$8.00. On average, they anticipate Cardiol Therapeutics' share price to reach C$5.83 in the next twelve months. This suggests a possible upside of 200.7% from the stock's current price.
Why is the price of a stock going down?
CRDL | Complete Cardiol Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
Is CRDL stock a good buy?
Out of 2 analysts, 2 (100%) are recommending CRDL as a Strong Buy, 0 (0%) are recommending CRDL as a Buy, 0 (0%) are recommending CRDL as a Hold, 0 (0%) are recommending CRDL as a Sell, and 0 (0%) are recommending CRDL as a Strong Sell. What is CRDL's earnings growth forecast for 2022-2024?
Will CRDL go up?
Cardiol Therapeutics Inc (NASDAQ:CRDL) The 3 analysts offering 12-month price forecasts for Cardiol Therapeutics Inc have a median target of 6.00, with a high estimate of 8.76 and a low estimate of 3.12. The median estimate represents a +197.03% increase from the last price of 2.02.
What does cardiol therapeutics do?
Cardiol Therapeutics Inc. is a life sciences company. The Company focuses on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease. Cardiol Therapeutics serves patients in Canada.
Is cardiol Therapeutics a good investment?
Cardiol Therapeutics has received a consensus rating of Buy.
Is cardiol Therapeutics a good stock to buy?
The Cardiol Therapeutics Inc. Class A stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average.
When did cardiol Therapeutics go public?
Cardiol Therapeutics went public with an initial public offering and commenced trading on the TSX Exchange on December 20, 2018.
Is Cardiol Therapeutics a buy right now?
3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cardiol Therapeutics in the last twelve months. There are current...
Are investors shorting Cardiol Therapeutics?
Cardiol Therapeutics saw a increase in short interest in January. As of January 31st, there was short interest totaling 381,000 shares, an increase...
When is Cardiol Therapeutics' next earnings date?
Cardiol Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 14th 2022. View our earnings forecast for C...
What price target have analysts set for CRDL?
3 brokers have issued 1-year price objectives for Cardiol Therapeutics' stock. Their forecasts range from $5.00 to $8.00. On average, they anticipa...
Who are Cardiol Therapeutics' key executives?
Cardiol Therapeutics' management team includes the following people: David G. Elsley , President, Chief Executive Officer & Director Bernard Lim...
Who are some of Cardiol Therapeutics' key competitors?
Some companies that are related to Cardiol Therapeutics include Stereotaxis (STXS) , Nabriva Therapeutics (NBRV) , CytomX Therapeutics (CTMX) ,...
What is Cardiol Therapeutics' stock symbol?
Cardiol Therapeutics trades on the NASDAQ under the ticker symbol "CRDL."
Who are Cardiol Therapeutics' major shareholders?
Cardiol Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include MMCAP International...
Which major investors are selling Cardiol Therapeutics stock?
CRDL stock was sold by a variety of institutional investors in the last quarter, including Virtu Financial LLC, and Renaissance Technologies LLC.
What is Cardiol Therapeutics INc. stock symbol?
Cardiol Therapeutics INc. is a Canadian stock, trading under the symbol CRDL-T on the Toronto Stock Exchange (undefined). It is usually referred to...
Is Cardiol Therapeutics INc. a buy or a sell?
In the last year, there was no coverage of Cardiol Therapeutics INc. published on Stockchase.
Is Cardiol Therapeutics INc. a good investment or a top pick?
Cardiol Therapeutics INc. was never recommended as a Top Pick on Stockchase. Read the latest stock expertsratings for Cardiol Therapeutics INc..
Why is Cardiol Therapeutics INc. stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should b...
Is Cardiol Therapeutics INc. worth watching?
0 stock analysts on Stockchase covered Cardiol Therapeutics INc. In the last year. It is a trending stock that is worth watching.
What is Cardiol Therapeutics INc. stock price?
On 2022-03-10, Cardiol Therapeutics INc. (CRDL-T) stock closed at a price of $1.68.
Cardiol Therapeutics INc. (CRDL-T)
COVID-19 heart issues? The company makes a synthetic CBD. Their original work saw CBD helped to reduce inflammation of the heart. It is expected they will start to re-purpose their product for COVID patients. This would help accelerate testing by about 2 years. This could lead to product being sold in Canada very quickly. A great opportunity.
Cardiol Therapeutics INc. (CRDL-T)
They struck a deal with Noramco, to sell into Canada and Mexico, synthetic CPD (for heart medication). They have enough cash to self finance the heart research.
Cardiol Therapeutics INc. (CRDL-T)
He has met management twice and they had their IPO in mid-December. They have looked into the use of CBD to use as an anti-inflammatory for heart patients. They are working on developing synthetic CBD. They think they could produce 1 millions grams of CBD this year.
Cardiol Therapeutics INc. (CRDL-T) Rating
Stockchase rating for Cardiol Therapeutics INc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.
Cardiol Therapeutics INc. (CRDL-T) Frequently Asked Questions
Cardiol Therapeutics INc. is a Canadian stock, trading under the symbol CRDL-T on the Toronto Stock Exchange (CRDL-CT). It is usually referred to as TSX:CRDL or CRDL-T
About Cardiol Therapeutics
Cardiol Therapeutics Inc., a clinical-stage biotechnology company, focuses on the research and development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD).
3.3 Analyst's Opinion
Cardiol Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Is Cardiol Therapeutics a buy right now?
3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cardiol Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock.
What price target have analysts set for CRDL?
3 brokers have issued 12-month target prices for Cardiol Therapeutics' shares. Their forecasts range from C$5.00 to C$8.00. On average, they expect Cardiol Therapeutics' share price to reach C$6.17 in the next twelve months.
Who are some of Cardiol Therapeutics' key competitors?
Some companies that are related to Cardiol Therapeutics include Liberty Health Sciences (LHSIF), RIV Capital (RIV), Willow Biosciences (WLLW), MediPharm Labs (LABS), Khiron Life Sciences (KHRN), FSD Pharma (HUGE), Meta Growth (META), Delta 9 Cannabis (DN), Jupiter Wellness (JUPW), 48North Cannabis (NRTH), Kaya (KAYSD), 1933 Industries (TGIFF), 4Front Ventures (FFNTF), AB Science (ABSCF) and Abattis Bioceuticals (ATT). View all of CRDL's competitors..
What is Cardiol Therapeutics' stock symbol?
Cardiol Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "CRDL."
How do I buy shares of Cardiol Therapeutics?
Shares of CRDL and other Canadian stocks can be purchased through an online brokerage account.
Signals & Forecast
A buy signal was issued from a pivot bottom point on Wednesday, February 23, 2022, and so far it has risen 10.27%. Further rise is indicated until a new top pivot has been found. Cardiol Therapeutics Inc. Class A has increased volume and follows the last lift in the price.
Support, Risk & Stop-loss
Cardiol Therapeutics Inc. Class A finds support from accumulated volume at $2.01 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Is Cardiol Therapeutics Inc. Class A stock A Buy?
Cardiol Therapeutics Inc. Class A holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
Signals & Forecast
The Baudax Bio Inc stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock.
Support, Risk & Stop-loss
There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.
Is Baudax Bio Inc stock A Buy?
Baudax Bio Inc holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
Insiders are very positive buying more shares than they are selling in Baudax Bio Inc
In the last 69 trades there were 12.75 million shares bought and 9.38 million shares sold. The last trade was done 66 days ago by Henwood Geraldine who bough 821.17 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
